Clinical Trial News and Research

RSS

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

AMAG Pharmaceuticals, Inc. today announced positive new data from the FIRST head-to-head trial comparing Feraheme (ferumoxytol) Injection for intravenous (IV) use to iron sucrose in patients with iron deficiency anemia and chronic kidney disease.

14 Nov 2011

Maintaining normal blood glucose levels prevents long-term kidney complications

Maintaining good glucose control early in the course of type 1 diabetes could lessen the long-term risk of kidney disease, as measured by a common test of kidney function.

14 Nov 2011

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Some blood-sugar-lowering drugs have caused kidney problems in patients with type 2 diabetes, so physicians are especially cautious when prescribing these agents to diabetics who also have chronic kidney disease.

14 Nov 2011

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

Perelman School of Medicine at the University of Pennsylvania faculty will be involved in presenting research findings on the latest advances in cardiovascular medicine, science, and education at the 2011 American Heart Association Scientific Sessions, in Orlando, FL, November 12 - 16, 2011.

14 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Salt – is it bad for the heart? Debate continues

Salt or high sodium intake in diet has drawn attention of researchers for a while now. The U.S. Food and Drug Administration held a day-long hearing today, discussing strategies to help Americans cut the salt from their diets as a latest attempt to curb sodium in the American diet.

13 Nov 2011

NeoStem third quarter revenues increase to $17.8 million

NeoStem, Inc., an international biopharmaceutical company with a focus on cell based therapeutics development, today reported third quarter results and recent progress in its business.

11 Nov 2011

Ampion safe and effective for patients with nasal inflammation

Ampio Pharmaceuticals, Inc., a company that discovers and develops new uses for previously approved drugs and new molecular entities, today announced that an IRB approved, randomized, vehicle-controlled, double-blinded study conducted at Centers for Allergy and Asthma in Denver, Colorado indicates that Ampion provides safe and effective anti-inflammatory relief when administered intranasally to patients with nasal inflammation.

11 Nov 2011

FDA draft guidance aims to foster early-stage development of medical devices

The U.S. Food and Drug Administration today issued a draft guidance aimed at fostering early-stage development of medical devices within the United States. Doing early-stage development is important to help stimulate U.S.-based innovation and contribute to medical research.

11 Nov 2011

Drug effectively combats obesity in “couch potato” monkeys” Study

According a new study an experimental anti-cancer drug could help fight obesity. The drug chokes off the blood supply to fat cells and helped obese monkeys slim down in the experiments.

10 Nov 2011

ArQule, Daiichi Sankyo enter license agreement for development of new AKT inhibitor

ArQule, Inc. and Daiichi Sankyo, Co. Ltd. announced today the execution of a license agreement for the development of a new AKT inhibitor called ARQ 092, the first compound to emerge from the companies' November 2008 agreement to collaborate on research utilizing the AKIP (ArQule Kinase Inhibitor Platform) technology to generate novel, selective and potent small molecule kinase inhibitors.

10 Nov 2011

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

Six-month results from the DELUX registry and 12-month results from the PEPPER study, both demonstrating excellent safety and efficacy results for the Pantera Lux Paclitaxel Releasing Balloon, were presented on Tuesday and Wednesday at the Transcatheter Cardiovascular Therapeutics (TCT 2011) conference by Dr. Ralph Toelg, MD, Segeberger Heart Center Clinic, Bad Segeberg, Germany, and Prof. Christoph Hehrlein, MD, University Medical Center, Freiburg, Germany, respectively.

10 Nov 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

GenMark Diagnostics, Inc. today reported financial results for the third quarter ended September 30, 2011.

10 Nov 2011

IRCM peptide chemist listed as inventor on two U.S. patents

In 2010, after more than 10 years of basic research, Dr. Peter W. Schiller, a world-renowned peptide chemist and Director of the Chemical Biology and Peptide research unit at the Institut de recherches cliniques de Montr-al (IRCM), and his international collaborators were the listed inventors on two U.S. patents awarded to the institute and covering different uses of a unique class of peptide compounds initially synthesized in Dr. Schiller's laboratory at the IRCM.

10 Nov 2011

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Obese rhesus monkeys lost on average 11 percent of their body weight after four weeks of treatment with an experimental drug that selectively destroys the blood supply of fat tissue, a research team led by scientists at The University of Texas MD Anderson Cancer Center reports in Science Translational Medicine.

10 Nov 2011

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Tailored anti-platelet therapy, made possible through a novel point-of-care genetic test, optimizes treatment for patients who carry a common genetic variant, researchers at the University of Ottawa Heart Institute (UOHI) have found.

10 Nov 2011

Combination of azacitidine and entinostat shows promise against NSCLC

A new type of therapy aimed at reversing the gene-silencing that promotes cancer-cell growth has shown promising results in a small clinical trial conducted by researchers at the Johns Hopkins Kimmel Cancer Center.

10 Nov 2011

Positive results from InSeal's intravascular large bore puncture closure device trial

InSeal Medical Ltd., developer of percutaneous vascular closure devices for large bore punctures, today announced the successful treatment of three patients with its investigational intravascular large bore puncture closure device.

10 Nov 2011

Study: Omega-3 supplements can decrease inflammation, anxiety

A recent study gauging the impact of consuming more fish oil showed a marked reduction both in inflammation and, surprisingly, in anxiety among a cohort of healthy young people.

10 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Clinical Trial News and Research

Feraheme as safe and effective as iron sucrose in patients with anemia, CKD

Maintaining normal blood glucose levels prevents long-term kidney complications

Sitagliptin as safe and effective as glipizide in patients with type 2 diabetes, CKD

Latest advances in cardiovascular medicine, science and education to be presented at AHA 2011

IVI receives WHO prequalification for new oral cholera vaccine

Salt – is it bad for the heart? Debate continues

NeoStem third quarter revenues increase to $17.8 million

Ampion safe and effective for patients with nasal inflammation

FDA draft guidance aims to foster early-stage development of medical devices

Drug effectively combats obesity in “couch potato” monkeys” Study

ArQule, Daiichi Sankyo enter license agreement for development of new AKT inhibitor

Positive results from BIOTRONIK Pantera Lux Paclitaxel Releasing Balloon study presented at TCT 2011

GenMark Diagnostics third quarter revenues increase 90% to $1.3 million

IRCM peptide chemist listed as inventor on two U.S. patents

Experimental drug selectively destroys blood supply of fat tissue and decreases body fat

Tailored anti-platelet therapy optimizes treatment for patients wtih common genetic variant

Combination of azacitidine and entinostat shows promise against NSCLC

Positive results from InSeal's intravascular large bore puncture closure device trial

Study: Omega-3 supplements can decrease inflammation, anxiety

Idera third quarter net loss increases to $5.5 million

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer